News stories about Kala Pharmaceuticals (NASDAQ:KALA) have trended somewhat positive on Monday, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Kala Pharmaceuticals earned a coverage optimism score of 0.06 on Accern’s scale. Accern also gave press coverage about the company an impact score of 47.3746981925413 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Several equities research analysts have commented on KALA shares. Bank of America Corporation started coverage on Kala Pharmaceuticals in a research note on Monday, August 14th. They issued a “buy” rating and a $33.00 target price on the stock. Wedbush started coverage on Kala Pharmaceuticals in a research note on Monday, August 14th. They issued an “outperform” rating and a $46.00 target price on the stock. J P Morgan Chase & Co started coverage on Kala Pharmaceuticals in a research note on Monday, August 14th. They issued an “overweight” rating and a $35.00 target price on the stock. Wells Fargo & Company started coverage on Kala Pharmaceuticals in a research note on Monday, August 14th. They issued an “outperform” rating and a $24.00 target price on the stock. Finally, Oppenheimer Holdings, Inc. started coverage on Kala Pharmaceuticals in a research note on Tuesday, August 15th. They issued an “outperform” rating and a $46.00 target price on the stock. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Kala Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $36.80.
Shares of Kala Pharmaceuticals (NASDAQ:KALA) opened at $20.42 on Monday. The company has a quick ratio of 11.00, a current ratio of 11.00 and a debt-to-equity ratio of 0.14. Kala Pharmaceuticals has a 12 month low of $13.51 and a 12 month high of $26.75.
Kala Pharmaceuticals (NASDAQ:KALA) last released its earnings results on Tuesday, November 7th. The company reported ($0.56) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.14). analysts predict that Kala Pharmaceuticals will post -2.08 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://transcriptdaily.com/2017/11/27/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-kala-pharmaceuticals-kala-share-price.html.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.
Receive News & Ratings for Kala Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.